Latest news

Australians living with MPN step closer to accessing Pegasys treatment [Publish Date: 08/06/2017]

The drug interferon alfa-2a (Pegasys®) was finally listed on the agenda of the Pharmaceutical Benefits Advisory Committee (PBAC) meeting on March 8 and many Australians are awaiting the results of the discussion.

For Nathalie Cook, who was diagnosed with MPN in 2008, this achievement was especially exciting after six years

Read More

Life-saving Hodgkin lymphoma treatment now available on PBS [Publish Date: 02/04/2017]

Participants of two Leukaemia Foundation surveys have helped inform the Pharmaceutical Benefits Advisory Committee of the benefits of brentuximab vedotin, a potentially life-saving treatment for Australians diagnosed with a form of Hodgkin lymphoma*, supporting its listing on the PBS from April 1.

The PBS listing of brentuximab vedotin gives individuals

Read More

Ageing population increasing Queensland’s blood cancer burden [Publish Date: 17/01/2017]

Blood cancer death rates in Queensland have soared by a third in just 10 years, a further symptom of the country’s ageing population, according to a new analysis.

The Leukaemia Foundation’s investigation shows the number of Australians dying from blood cancer is now DOUBLE those losing their life to melanoma¹.

Latest

Read More

Breakthrough cancer drug venetoclax approved for use in Australia [Publish Date: 10/01/2017]

New anti-cancer drug, venetoclax which has the power to ‘melt away’ advanced forms of chronic lymphocytic leukaemia (CLL) was recently granted approval by the Australian Therapeutic Goods Administration (TGA).

The drug will be marketed as VenclextaTM and is approved for Australians with relapsed or refractory CLL with 17p

Read More

Holden donates 17 Commodores to help Australians get to life-saving treatment [Publish Date: 29/10/2016]

Finding a way to attend vital appointments can be an added burden to someone already facing a life-threatening blood cancer diagnosis.

Holden are helping to alleviate this stress and provide better journeys to treatment by supplying the Leukaemia Foundation’s nationwide Patient Transport Program with 17 new Commodores.

Getting to and from

Read More

Streamlined approvals to improve access to lifesaving medicines [Publish Date: 25/10/2016]

The Leukaemia Foundation welcomes the Australian Government’s commitment to new reforms to improve the way medicines are accessed for use in Australia.

By helping to streamline access to medicines and medical devices including access to novel and life-saving therapies, the reforms aim to strike a balance by removing unnecessary red

Read More

Building of Hope opens [Publish Date: 30/09/2016]

The Leukaemia Foundation was thrilled to officially open the doors to the Building of Hope, the new Victorian Patient Accommodation Centre on Wednesday July 13.

The occasion was marked by an official ribbon cutting ceremony, attended by the Minister for Health, Hon Jill Hennessy. Minister Hennessy was given a tour of

Read More

Towards better treatment outcomes in lymphoma by personalising medicine [Publish Date: 01/09/2016]

New directions in treatment for lymphoma are increasingly based on ‘personalised medicine’, which means identifying the best treatment for an individual patient.

The Leukaemia Foundation’s Head of Blood Cancer Support, Anthony Steele, said the overall aim of this approach was to optimise treatment outcomes.

“Currently, we do not have enough information

Read More

Targeted therapies offer fresh hope for AML [Publish Date: 22/07/2016]

The results of a clinical trial involving a new combination therapy of Venetoclax and chemotherapy are providing hope for Australians diagnosed with AML

Clinical and translational AML researcher, Dr Andrew Wei and his teams at the Alfred Hospital and Monash University, are optimistic about the combination therapy, with between 60

Read More

High-tech scans spare lymphoma patients intensive chemo [Publish Date: 27/06/2016]

Illustration of lymphoma study results

The use of PET scans can spare Hodgkin lymphoma (HL) patients from the serious effects of chemotherapy thanks to a study supported by the Leukaemia Foundation*.

Results of a study, published in the New England Journal

Read More

Share this page

X
X